|
Jul 29
|
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
|
|
Jul 24
|
European Value Stocks That Could Be Trading Below Their Estimated Worth In July 2025
|
|
Jun 25
|
European Stocks That May Be Trading Below Estimated Value In June 2025
|
|
Jun 24
|
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
|
|
May 22
|
European Stock Picks That May Be Undervalued In May 2025
|
|
Mar 3
|
3 European Stocks Estimated To Be Undervalued In March 2025
|
|
Feb 13
|
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
|